Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: AIDS Behav. 2015 Mar;19(3):459–471. doi: 10.1007/s10461-014-0971-0

Fig. 3.

Fig. 3

Dose timing windows are significantly smaller for antiretroviral medications among iTAB participants as compared to control *p < 0.05. ARV antiretroviral medications, CTRL participants assigned to the control arm, iTAB participants assigned to the individualized Texting for Adherence Building arm, PSY psychotropic medications